OR-1855
OR-1855, an active metabolite of Levosimendan , has effect on myometrial contractility. OR-1855 exerts anti-inflammatory effects by inhibiting IL-1β-induced ROS formation and NAD (P) H oxidase-dependent superoxide radical generation in HUVECs. OR-1855 inhibits IL-1β-induced phosphorylation p38 MAPK, ERK1/2, c-Jun and JNK in HUVECs. OR-1855 can be used for the study of inflammation[1][2][3].
Product Specifications
CAS Number
101328-85-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Drug Metabolite; ERK; p38 MAPK; Reactive Oxygen Species (ROS)
Type
Reference compound
Related Pathways
Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/or-1855.html
Concentration
10mM
Purity
99.78
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1C[C@@H](C)C(C2=CC=C(N)C=C2)=NN1
Molecular Formula
C11H13N3O
Molecular Weight
203.25
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Wilm s Tumor 1 (WT1) (Wilm s Tumor & Mesothelial Marker) (rWT1/857), CF594 conjugate, 0.1mg/mL
